Ad hoc: Carl Zeiss Meditec achieved sales growth in the first six months of the financial year 2012/2013 of around 3%

Tuesday, 02. April 2013 14:07

Carl Zeiss Meditec AG / Quarterly report / Ad hoc: Carl Zeiss Meditec achieved sales growth in the first six months of the financial year 2012/2013 of around 3% . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Jena, 2 April 2013: In the first six months of the financial year 2012/2013, Carl Zeiss Meditec has achieved a turnover of approx. € 442 million (previous year: € 431.8 million), which corresponds to a growth compared to the previous year of around 3%. Adjusted for currency effects, revenues increased by approximately 4%.

Sales in the Microsurgery strategic business unit grew in the first six months of the current financial year by about 6% compared to last year and reached approximately € 207 million (previous year: € 195.1 million).

In the Ophthalmic Systems strategic business unit revenues of approximately  € 176 million (previous year: € 184.8 million) were achieved, which corresponds to a decline of around 5%. Although order intake in this business unit developed well compared to last year, revenue generation in the second quarter was somewhat slower than expected, meaning that it remains uncertain whether the target of at least equaling market growth can be achieved by the end of the current financial year.

The Surgical Ophthalmology strategic business unit continued its positive development. Sales in the first 6 months grew by around 16% compared to the previous year and amounted to approximately € 60 million (previous year: € 51.9 million).

Contact for investors
Henriette Meyer, Director Investor Relations, Carl Zeiss Meditec AG
Tel. +49 3641 220-106, E-Mail:

Press contact
Jann Gerrit Ohlendorf, Director Corporate Communications, Carl Zeiss Meditec AG Tel. +49 3641 220-331, E-Mail:

Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In financial year 2011/2012 (ended 30 September) the Group's more than 2,400 employees generated revenue of almost € 862 million. The head office of Carl Zeiss Meditec is in Jena, Germany.

The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.
For more than 160 years Carl Zeiss has been contributing to the progress of technology on the markets for Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics, improving the quality of life for many people. Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss Foundation.

For more information visit our website at:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Carl Zeiss Meditec AG via Thomson Reuters ONE


--- End of Message ---

Carl Zeiss Meditec AG
Goeschwitzer Strasse 51-52 Jena Germany

WKN: 531370;ISIN: DE0005313704;Index:Prime All Share,TECH All Share,TecDAX;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;

Related Links: Carl Zeiss Meditec AG
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.